替格瑞洛对冠心病患者PCI治疗术后冠脉微循环功能的影响

Effect of Ticagrelor on Coronary Microcirculation Function in Patients with Coronary Heart Disease After PCI Treatment

目的分析替格瑞洛应用于冠心病患者经皮冠状动脉介入(PCI)治疗术后,对冠脉微循环功能的影响。方法选取2018年1月~2019年1月在我院进行PCI术治疗的50例冠心病患者为研究对象,采用随机数字表法分为对照组和观察组,各25例。对照组采用氯吡格雷,观察组采用替格瑞洛,比较治疗后两组凝血酶原时间(PT)、血小板聚集率(PAgT)和纤维蛋白原(Fbg)含量、循环抵抗指数(IMR)、超氧化物歧化酶(SOD)、丙二醛(MDA)、冠脉血流储备(CFR)、临床不良反应(呼吸困难、轻度出血)发生率及心血管事件发生情况。结果治疗后观察组PT、PAgT、Fbg、IMR、MDA低于对照组,CFR、SOD高于对照组(P<0.05);治疗后观察组不良反应发生率为8.00%,与对照组的4.00%比较,差异无统计学意义(P>0.05);治疗后6个月观察组心血管事件发生率为4.00%,低于对照组的20.00%(P<0.05)。结论冠心病患者PCI术后应用替格瑞洛治疗,有助于改善冠脉微循环功能和凝血功能,临床不良反应少,且可降低远期心血管不良事件发生率,值得临床应用。

Objective To analyze the effect of ticagrelor on coronary microcirculation function after percutaneous coronary intervention(PCI)treatment in patients with coronary heart disease.Methods 50 patients with coronary heart disease who underwent percutaneous coronary intervention in our hospital from January 2018 to January 2019 were selected as the research object.They were divided into a control group and an observation group with a random number table method,25 cases each.Clopidogrel was used in the control group and ticagrelor was used in the observation group.After treatment,the two groups of thrombin time(PT),platelet aggregation rate(PAgT),fibrinogen(Fbg)content,circulating resistance index(IMR)the incidence of superoxide dismutase(SOD),malondialdehyde(MDA),coronary flow reserve(CFR),clinical adverse reactions(dyspnea,mild bleeding)and the occurrence of cardiovascular events.Results The PT,PAgT,Fbg,IMR and MDA of the observation group after treatment were lower than the control group,and the CFR and SOD were higher than the control group(P<0.05);the incidence of adverse reactions in the observation group after surgery was 8.00%,and compared with 4.00%of the control group,the difference was not statistically significant(P>0.05);the incidence of cardiovascular events in the observation group at 6 months after surgery was 4.00%,which was lower than 20.00%of the control grou(P<0.05).Conclusion The use of ticagrelor in patients with coronary heart disease after PCI is helpful to improve coronary microcirculation function and coagulation function,has fewer clinical adverse reactions,and can reduce the incidence of long-term cardiovascular adverse events.It is worthy of clinical application.